Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Maasoumy, Benjamin ^a   Hunyady, Bela ^b,c   Calvaruso, Vincenza ^d   Makara, Mihály ^e   Vermehren, Johannes ^f   Haragh, Attila ^b   Susser, Simone ^f   Bremer, Birgit ^a   Cloherty, Gavin ^g   Manns, Michael P ^a   Craxì, Antonio ^d   Wedemeyer, Heiner ^a   Sarrazin, Christoph ^f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Kaposi Mor Teaching Hospital   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

^d UNIVERSITY OF PALERMO   (Italy)

^e Szent Laszlo Hospital   (Hungary)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g Abbott Molecular Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; TELAPREVIR; VIRUS RNA; ANTIRETROVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR;

ARTICLE; BIOASSAY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; DISEASE COURSE; DRUG RESPONSE; FEMALE; HEPATITIS C VIRUS; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSTICS; MULTICENTER STUDY; NONHUMAN; POLYMERASE CHAIN REACTION SYSTEM; PREDICTIVE VALUE; RISK BENEFIT ANALYSIS; RNA ANALYSIS; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL PHENOMENA AND FUNCTIONS; VIRUS EXAMINATION; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; DRUG EFFECTS; ENZYMOLOGY; EUROPE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; REPRODUCIBILITY; VIREMIA; VIROLOGY;

HEPATITIS C VIRUS;

ANTI-RETROVIRAL AGENTS; CLINICAL LABORATORY TECHNIQUES; EUROPE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; OLIGOPEPTIDES; PREDICTIVE VALUE OF TESTS; PROLINE; PROTEASE INHIBITORS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; TREATMENT OUTCOME; VIREMIA;

EID: 84912003692     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110857     Document Type: Article

References (42)

1. Maasoumy B, Wedemeyer H (2012) Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26: 401-412. 2
2. (2014) EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 60: 392-420.
3. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-2593.
4. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, et al. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207-1217.
5. Poordad F, McCone JJ, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
6. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, et al. (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014-1024.
7. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
8. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al. (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-2428.
9. You DM, Pockros PJ (2013) Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 14: 2581-2589.
10. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, et al. (2013) Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 310: 804-811.
11. Younossi Z.M. , Stepanova M., Henry L., Gane E., Jacobson I.M., et al. (2013) Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C). J Hepatol
12. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, et al. (2013) Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 8: e55285.
13. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, et al. (2013) Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 59: 434-441.
14. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA (2014) Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 39: 93-103.
15. Pfeiffer KH, Gerber L, Susser S, Vermehren J, Perner D, et al. (2012) Significant differences between different assays for assessment of HCV RNA undetectability during response guided therapy in patients treated with PEG-Interferon, Ribavirin with or without a protease inhibitor. Hepatology 56: 560A.
16. Harrington PR, Zeng W, Naeger LK (2012) Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 55: 1048-1057.
17. Maasoumy B, Cobb B, Bremer B, Luk K, Halfon P, et al. (2014) Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther 39: 85-92.
18. Vermehren J, Yu ML, Monto A, Yao JD, Anderson C, et al. (2011) Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. J Clin Virol 52: 133-137.
19. Zitzer H, Heilek G, Truchon K, Susser S, Vermehren J, et al. (2013) Secondgeneration Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 51: 571-577.
20. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433-1444.
21. Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, et al. (2012) [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 50: 57-72.
22. Chevaliez S, Rodriguez C, Pawlotsky JM (2012) New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142: 1303-1313.e1.
23. Cobb B, Pockros PJ, Vilchez RA, Vierling JM (2013) HCV RNA viral load assessments in the era of direct-acting antivirals. Am J Gastroenterol 108: 471-475.
24. Wedemeyer H, Kessler HH, Michel-Treil V, Bremer B, Hu?bner M, et al. (2012) The ExPECT study: An international multicenter clinical trial evaluating low HCV RNA viremia with the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 compared to assays used in routine clinical practise and in drug trials. Hepatology 56 (Supplement): 676A-677A.
25. Fevery B, Susser S, Lenz O, Cloherty G, Perner D, et al. (2014) HCV RNA quantification with different assays: implications for protease inhibitor-based response-guided therapy. Antivir Ther.
26. Vermehren J, Aghemo A, Falconer K, Susser S, Lunghi G, et al. (2014) Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. J Hepatol.
27. Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, et al. (2012) Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 56: 567-575.
28. th June 2013, Singapore.
29. Michelin BD, Muller Z, Stelzl E, Marth E, Kessler HH (2007) Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol 38: 96-100.
30. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, et al. (2008) Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 46: 3880-3891.
31. Vermehren J, Colucci G, Gohl P, Hamdi N, Abdelaziz AI, et al. (2011) Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol 49: 3309-3315.
32. Koff RS (2014) Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 39: 478-487.
33. Feld JJ (2014) The beginning of the end: What is the future of interferon therapy for chronic hepatitis C? Antiviral Res.
34. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, et al. (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370: 1483-1493.
35. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, et al. (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370: 1889-1898.
36. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, et al. (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370: 1879-1888.
37. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, et al. (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet.
38. Sulkowski MS, Jacobson IM, Nelson DR (2014) Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 370: 1560-1561.
39. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, et al. (2014) Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370: 1594-1603.
40. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, et al. (2014) ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370: 1983-1992.
41. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, et al. (2014) ABT- 450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370: 1973-1982.
42. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, et al. (2014) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370: 1993-2001.